Literature DB >> 17487448

HLA class 1 associations in Henoch Schonlein purpura: increased and decreased frequencies.

Harun Peru1, Oguz Soylemezoglu, Sevim Gonen, Aysun Cetinyurek, Sevcan Azime Bakkaloğlu, Necla Buyan, Enver Hasanoglu.   

Abstract

Henoch Schonlein purpura (HSP) is the most common vasculitis of childhood. Susceptibility to HSP and associated clinical heterogeneity in HSP may be conferred by a number of genetic loci, including the major histocompatibility complex. We aimed to investigate the implications of the human leukocyte antigen (HLA) class 1 alleles in susceptibility to HSP and determine the possible associations with renal, gastrointestinal (GI), and joint manifestations of the disease. 110 children with HSP (66 boys, 44 girls) and 250 unrelated healthy controls were enrolled in the study. The mean age was 8.65 +/- 3.59 years. HSP was diagnosed on the basis of clinical and laboratory data according to the American College of Rheumatology classification. The diagnosis was supported with skin and/or kidney in most of the patients. Clinical and laboratory findings revealed: skin involvement in 110 (100%), joint manifestations in 82 (74.5%), GI symptoms in 58 (52.7%), and hematuria and/or proteinuria in 36 (32.7%) patients. HLA class 1 alleles were identified by DNA amplification, hybridized with specific primer sequences. Comparison of frequencies between patients and controls were made by using the Fisher's exact test. Odds ratio (OR) was used as the measure of association. HLA A2, A11, and B35 antigens showed an increased risk for predisposition to HSP (OR = 1.714, 95%CI = 1.088-2.700, p = 0.020; OR = 2.185, 95%CI = 1.289-3.703, p = 0.003; and OR = 2.292, 95%CI = 1.451-3.619, p = 0.000, respectively), while HLA A1, B49, and B50 antigens revealed decreased risk for predisposition to HSP (OR = 4.739, 95%CI = 1.828-12.345, p = 0.001; OR = 3.268, 95%CI = 0.955-11.236, p = 0.047; and OR = 7.462, 95%CI = 0.975-55.555, p = 0.024, respectively). Considering the renal involvement and severity of proteinuria, there was no association with HLA class 1 alleles. Our results suggest that the increased frequency of HLA A2, A11, and B35 alleles in unselected pediatric HSP patient population and miscarrying of HLA A1, B49, and B50 could be considered as a risk factor for susceptibility to HSP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487448     DOI: 10.1007/s10067-007-0640-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  [Histocompatibility antigens and acute vascular purpura].

Authors:  J Arellano; S Ojeda; R Vargas; C Zavala; D Santos; A López; R Kretschmer
Journal:  Bol Med Hosp Infant Mex       Date:  1990-09

2.  The HLA system in glomerulonephritis.

Authors:  S Nyulassy; M Buc; M Sasinka; M Pavlovic; I Slugen; V Hirschová; M Kaiserová; R Menkyna; J Stefanovic
Journal:  Clin Immunol Immunopathol       Date:  1977-05

3.  HLA-DRB1*01 association with Henoch-Schönlein purpura in patients from northwest Spain.

Authors:  M M Amoli; W Thomson; A H Hajeer; M C Calviño; C Garcia-Porrua; W E Ollier; M A Gonzalez-Gay
Journal:  J Rheumatol       Date:  2001-06       Impact factor: 4.666

4.  Nitric oxide in Henoch-Schönlein purpura.

Authors:  Oğuz Söylemezoğlu; Ozan Ozkaya; Deniz Erbaş; Nermin Akkök; Necla Buyan; Enver Hasanoğlu
Journal:  Scand J Rheumatol       Date:  2002       Impact factor: 3.641

5.  Immunogenetics of Henoch-Schoenlein disease.

Authors:  A Amoroso; M Berrino; L Canale; R Coppo; M Cornaglia; S Guarrera; G Mazzola; F Scolari
Journal:  Eur J Immunogenet       Date:  1997-10

6.  HLA-B35 association with nephritis in Henoch-Schönlein purpura.

Authors:  Mahsa M Amoli; Wendy Thomson; Ali H Hajeer; Maria C Calviño; Carlos Garcia-Porrua; William E R Ollier; Miguel A Gonzalez-Gay
Journal:  J Rheumatol       Date:  2002-05       Impact factor: 4.666

7.  Complement 4 locus II gene deletion and DQA1*0301 gene: genetic risk factors for IgA nephropathy and Henoch-Schönlein nephritis.

Authors:  D K Jin; T Kohsaka; J W Koo; I S Ha; H I Cheong; Y Choi
Journal:  Nephron       Date:  1996       Impact factor: 2.847

8.  Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis.

Authors:  O Rauzy; M Fort; F Nourhashemi; L Alric; H Juchet; M Ecoiffier; M Abbal; D Adoue
Journal:  Ann Rheum Dis       Date:  1998-06       Impact factor: 19.103

9.  HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis.

Authors:  C M Weyand; N N Hunder; K C Hicok; G G Hunder; J J Goronzy
Journal:  Arthritis Rheum       Date:  1994-04

10.  Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association.

Authors:  A Dababneh; M A Gonzalez-Gay; C Garcia-Porrua; A Hajeer; W Thomson; W Ollier
Journal:  J Rheumatol       Date:  1998-11       Impact factor: 4.666

View more
  12 in total

1.  Seizures, renal failure and acute respiratory failure: not your typical case of Henoch-Schonlein purpura.

Authors:  Subhasish Bose; Samata Pathireddy; Krishna M Baradhi; Narothama Reddy Aeddula
Journal:  BMJ Case Rep       Date:  2019-07-17

Review 2.  The genetics of Henoch-Schönlein purpura: a systematic review and meta-analysis.

Authors:  Xuelian He; Chunhua Yu; Peiwei Zhao; Yan Ding; Xiaohui Liang; Yulan Zhao; Xin Yue; Yanxiang Wu; Wei Yin
Journal:  Rheumatol Int       Date:  2013-01-17       Impact factor: 2.631

3.  CTLA-4 +49 A/G genotype and HLA-DRB1 polymorphisms in Turkish patients with Henoch-Schönlein purpura.

Authors:  Oguz Soylemezoglu; Harun Peru; Sevim Gonen; Aysun Cetinyurek; Ozan Ozkaya; Sevcan Bakkaloğlu; Necla Buyan; Enver Hasanoglu
Journal:  Pediatr Nephrol       Date:  2008-05-01       Impact factor: 3.714

4.  HLA-DQ and HLA-DRB1 alleles associated with Henoch-Schönlein purpura nephritis in Finnish pediatric population: a genome-wide association study.

Authors:  Mikael Koskela; Julia Nihtilä; Elisa Ylinen; Kaija-Leena Kolho; Matti Nuutinen; Jarmo Ritari; Timo Jahnukainen
Journal:  Pediatr Nephrol       Date:  2021-02-16       Impact factor: 3.714

5.  Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status.

Authors:  Raquel López-Mejías; Fernanda Genre; Belén Sevilla Pérez; Santos Castañeda; Norberto Ortego-Centeno; Javier Llorca; Begoña Ubilla; Sara Remuzgo-Martínez; Verónica Mijares; Trinitario Pina; Vanesa Calvo-Río; Ana Márquez; José A Miranda-Filloy; Antonio Navas Parejo; Marta Conde-Jaldón; Lourdes Ortiz-Fernández; Diego Argila; Maximiliano Aragües; Esteban Rubio; Manuel León Luque; Juan María Blanco-Madrigal; Eva Galíndez-Aguirregoikoa; Francisca González Escribano; J Gonzalo Ocejo-Vinyals; Javier Martín; Ricardo Blanco; Miguel A González-Gay
Journal:  Arthritis Res Ther       Date:  2015-04-14       Impact factor: 5.156

6.  A novel case of renal pathergy reaction in a Behçet's disease patient complicated by IgA vasculitis.

Authors:  Takaaki Higashihara; Akira Okada; Taiko Kusano; Kazuyoshi Ishigaki; Akira Shimizu; Hideki Takano
Journal:  BMC Nephrol       Date:  2017-01-28       Impact factor: 2.388

Review 7.  Vasculitis update: pathogenesis and biomarkers.

Authors:  Paul Brogan; Despina Eleftheriou
Journal:  Pediatr Nephrol       Date:  2017-08-07       Impact factor: 3.714

8.  Involvement of activated cytotoxic T lymphocytes and natural killer cells in Henoch-Schönlein purpura nephritis.

Authors:  Takashi Imai; Kei Nishiyama; Kenji Ueki; Tamami Tanaka; Yoshitsugu Kaku; Toshiro Hara; Shouichi Ohga
Journal:  Clin Transl Immunology       Date:  2020-11-24

Review 9.  A Review of the Mechanism of Vascular Endothelial Injury in Immunoglobulin A Vasculitis.

Authors:  Shanshan Xu; Shanshan Han; Yanlin Dai; Long Wang; Xia Zhang; Ying Ding
Journal:  Front Physiol       Date:  2022-03-16       Impact factor: 4.566

10.  Co-occurrence of Behçet disease with Ig A vasculitis revealed by ophtalmic examination: A case report.

Authors:  Ben Abdesslem Nadia; Mahjoub Ahmed; Tasnim Mhamdi; Mahjoub Hechemi; Knani Leila; Krifa Fethi
Journal:  Ann Med Surg (Lond)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.